Lupin与Takeda为印度的Vonoprazan片片取得非专属许可证。 Lupin secures non-exclusive license with Takeda for Vonoprazan tablets in India.

Lupin有限公司与Takeda制药公司签订了一项非排他性专利许可证协议,在印度销售Vonoprazan片片,名为Lupivon。 Lupin Limited has secured a non-exclusive patent licensing agreement with Takeda Pharmaceutical to market Vonoprazan tablets in India under the brand name Lupivon. 该药物是一种具有钾竞争力的酸阻塞剂,用10毫克和20毫克剂量供应,用于治疗各种胃肠病。 The drug, a potassium-competitive acid blocker, will be available in 10 mg and 20 mg doses for treating various gastrointestinal conditions. 这一伙伴关系旨在满足印度的重大保健需求,印度普遍存在酸性败血性失调症。 This partnership aims to address significant healthcare needs in India, where acid peptic disorders are prevalent. 公告发布后，Lupin 的股价下跌了 1.97%。 Following the announcement, Lupin's stock fell by 1.97%.